Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions [PDF]
Annals of Clinical and Translational Neurology, 2023 Objective Postpartum, patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) have increased risk for disease activity. Anti‐CD20 IgG1 monoclonal antibodies (mAb) are increasingly used as disease‐modifying therapies (DMTs)
Annika Anderson +22 more
doaj +2 more sources
Enhancement of effector functions of anti-CD20 monoclonal antibody by increased afucosylation in CHO cell line through cell culture medium optimization [PDF]
Journal of Genetic Engineering and Biotechnology, 2022 Background Recombinant therapeutic anti-CD20 monoclonal antibody (mAb) is used for the treatment of non-Hodgkin’s lymphoma, a common B cell lymphoma constituting 80% of all lymphomas. Anti-CD20 mAb contains an Fc-linked biantennary glycan. Although, anti-
Bala Reddy Bheemareddy +3 more
doaj +2 more sources
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in the treatment of severe refractory Anti-N-methyl-D-aspartate receptor encephalitis: Two case reports [PDF]
Annals of Indian Academy of Neurology, 2023 Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is a type of autoimmune encephalitis (AE) characterized by antibodies against NMDA receptor. As the most common AE, anti-NMDAR encephalitis affects 54% ~ 80% of patients with AE.
Hongfei Xue +8 more
doaj +2 more sources
Ofatumumab: a novel monoclonal anti-CD20 antibody
Pharmacogenomics and Personalized Medicine, 2010 Thomas S LinGlaxoSmithKline Oncology R&D, Collegeville, PA, USAAbstract: Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic
Thomas S Lin
doaj +6 more sources
Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report [PDF]
Respiratory Medicine Case Reports, 2021 A 71-year-old female patient with B-cell depletion due to treatment with an anti-CD20 monoclonal antibody was admitted for worsening COVID-19. Overall, she had persistent viral shedding, worsening respiratory failure, and progressive pneumonia that did ...
Ayham Daher +4 more
doaj +2 more sources
Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series [PDF]
Frontiers in ImmunologyIntroductionAnti-CD20 monoclonal antibody (mAb) therapies used to treat multiple sclerosis (MS) differ in their molecular structures, epitope recognition, and mechanisms of CD20-positive (CD20+) cell lysis, which may impact clinical efficacy and ...
Regina Berkovich +7 more
doaj +2 more sources
A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle. [PDF]
Sci Rep, 2018 AbstractThe monoclonal antibody (mAb) against CD20 known as Rituxan is widely used to treat autoimmune diseases and lymphomas. However, further application of Rituxan faces challenges of high production cost, which limits its availability in developing countries.
Zhang R +12 more
europepmc +4 more sources
Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus [PDF]
Biologicals, 2021 Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory condition with a wide spectrum of disease manifestations and severities, resulting in significant morbidity and mortality. The aetiopathogenesis of SLE is complex. Young women and certain ethnicities are commonly affected, suggesting a significant hormonal and genetic influence.
Shah, K, Cragg, M, Leandro, M, Reddy, V
openaire +6 more sources
ACR Open Rheumatology, 2022 Objective Patients with immune‐mediated diseases treated with anti‐CD20 monoclonal antibodies may have worse coronavirus disease 2019 (COVID‐19) outcomes due to impaired humoral immunity, but differences compared with the general population are unknown ...
Naomi J. Patel +12 more
doaj +1 more source
Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
Brain Sciences, 2020 Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has been largely underestimated, and the disease was considered a T-cell-mediated disorder.
Despoina Florou +4 more
doaj +1 more source